



Mylan Announces Launch of Quinapril Tablets, USP and Quinapril Hydrochloride and Hydrochlorothiazide Tablets

PITTSBURGH, Feb. 28 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Quinapril Tablets USP, 5mg, 10mg, 20mg and 40mg strengths, and Quinapril Hydrochloride (HCl) and Hydrochlorothiazide (HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg strengths.

Quinapril Tablets and Quinapril HCl and HCTZ Tablets are the generic versions of Pfizer's Accupril[®] and Accuretic[®] Tablets, respectively. Quinapril Tablets had U.S. sales of approximately \$193 million for the 12 months ending December 2006. Quinapril HCl and HCTZ Tablets had U.S. sales of approximately \$37 million for the 12 months ending December 2006.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.

CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc.,
+1-724-514-1800
Web site: <http://www.mylan.com>